Galapagos NV (AMS:GLPG)

Market Cap	1.62B +11.4%
Revenue (ttm)	1.11B +303.5%
Net Income	320.88M +333.1%
EPS	4.87 +333.7%
Shares Out	65.90M
PE Ratio	5.07
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	42,565
Average Volume	99,254
Open	24.50
Previous Close	24.66
Day's Range	24.42 - 24.86
52-Week Range	20.70 - 32.74
Beta	0.15
RSI	34.80
Earnings Date	Mar 26, 2026

About Galapagos NV

Galapagos NV, a biotechnology company, develops medicines focusing on oncology and immunology primarily in the United States and Europe. The company’s pipeline products comprise GLPG3667 that is in phase 2 clinical trial in dermatomyositis and systemic lupus erythematosus; GLPG5101, a CD19 CAR-T product candidate manufactured at point-of-care, currently in Phase1/2 trial in relapsed/refractory non-hodgkin lymphoma; and GLPG5301, a BCMA CAR-T product candidate manufactured at point-of-care, currently in phase 1/2 in relapsed/refractory multiple ...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 1999
• Employees: 558
• Stock Exchange: Euronext Amsterdam
• Ticker Symbol: GLPG

Financial Performance

In 2025, Galapagos NV's revenue was 1.11 billion, an increase of 303.50% compared to the previous year's 275.65 million. Earnings were 320.88 million, an increase of 333.15%.